98%
921
2 minutes
20
Background: Helicobacter pylori (H. pylori) is recognized as a major risk factor for gastric cancer (GC). However, the precise mechanism by which H. pylori influences macrophage immune responses in cancer progression remains poorly understood. This study investigates how H. pylori affects macrophage polarization via the glucocorticoid receptor (NR3C1) and its subsequent role in gastric cancer cell proliferation.
Materials And Methods: NR3C1 expression, prognosis, and immune infiltration in gastric cancer were analyzed using the UCSC, TCGA, and GEPIA databases. NR3C1 expression, activation, macrophage polarization, and autophagy were assessed using RT-qPCR, Western blot, and immunofluorescence. IL-10 expression and secretion were quantified using RT-qPCR and ELISA. Reactive oxygen species (ROS) production was analyzed using flow cytometry and fluorescence microscopy. Western blot, flow cytometry, and functional assays also evaluated apoptosis, proliferation, and migration alterations.
Results: H. pylori infection induces the upregulation and activation of NR3C1 in macrophages. By modulating NR3C1 signaling, H. pylori promotes the immunosuppressive phenotype and triggers macrophage autophagy impairment. NR3C1 presence in macrophages enhances the active response to the H. pylori-induced immunosuppressive microenvironment. This leads to increased activity in gastric cancer cells (HGC-27), including enhanced proliferation, migration, reduced apoptosis, and elevated ROS production.
Conclusion: H. pylori orchestrates the immunosuppressive microenvironment of macrophages via NR3C1, promoting a malignant phenotype in gastric cancer cells and suggesting potential therapeutic targets for H. pylori-related gastric cancer treatment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.tice.2025.103001 | DOI Listing |
Signal Transduct Target Ther
September 2025
State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
Gastric Cancer
September 2025
Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
Background: Immune checkpoint inhibitors (ICIs) play a pivotal role in the treatment of advanced gastric cancer (GC). However, the biomarkers used to predict ICI efficacy are limited due to their reliance on single or static tumor characteristics. This study aims to develop a machine learning (ML) model that incorporates dynamic changes in clinlabomics data to optimize the predictive accuracy of ICI efficacy.
View Article and Find Full Text PDFNutr Clin Pract
September 2025
School of Biological, Health and Sports Sciences, Technological University Dublin, Dublin, Ireland.
Background: Esophagectomy causes anatomical changes that can lead to rapid food transit and reactive hypoglycemia (RH). Patients are advised on eating patterns postesophagectomy to prevent RH, but its true incidence and the impact of dietary recommendations remain under-researched.
Materials And Methods: Individuals >12 months postesophagectomy were recruited from the National Centre for Oesophageal and Gastric Cancer at St James's Hospital in Dublin, Ireland.
J Thorac Oncol
September 2025
Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan. Electronic address:
Free Radic Biol Med
September 2025
Department of General Surgery, Jiangnan University Medical Center, Wuxi, PR China. Electronic address:
In oxaliplatin-resistant gastric cancer (GC), multi-omics profiling combined with organoid libraries reveals altered metabolic pathways associated with chemoresistance. We identify a novel lactylation modification at K115 of Poly(RC)-binding protein 2 (PCBP2K115la), which confers functional oxaliplatin resistance. Mechanistic studies demonstrate that the long non-coding RNA BASP1-AS1 assembles a complex containing Unc-51 Like Autophagy Activating Kinase 1 (ULK1) and lactate dehydrogenase A (LDHA), thereby activating LDHA enzymatic activity to increase lactate production.
View Article and Find Full Text PDF